Zevia Q2 net sales rise 10.1%, beat expectations

Reuters
Aug 07
Zevia <a href="https://laohu8.com/S/QTWO">Q2</a> net sales rise 10.1%, beat expectations

Overview

  • Zevia Q2 net sales rise 10.1% to $44.5 mln, beating expectations

  • Adjusted EBITDA turns positive, beating analyst estimates, per LSEG data

  • Net loss narrows to $0.7 mln

Outlook

  • Zevia expects Q3 2025 net sales of $38 mln to $40 mln

  • Company expects 2025 adjusted EBITDA to reflect marketing reinvestment

Result Drivers

  • VOLUME GROWTH - Net sales increase driven by 14.3% volume growth, largely from expanded distribution at Walmart and drug channel

  • GROSS PROFIT MARGIN - Improvement in gross profit margin due to lower product costs and better inventory management

  • SELLING EXPENSES - Reduced selling expenses due to savings in freight and warehousing costs from Productivity Initiative

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Sales

Beat

$44.52 mln

$41.70 mln (5 Analysts)

Q2 EPS

-$0.01

Q2 Adjusted EBITDA

Beat

$200,000

-$2.45 mln (4 Analysts)

Q2 Gross Profit

$21.69 mln

Q2 Income from Operations

-$1.02 mln

Q2 Operating Expenses

$22.71 mln

Q2 Pretax Profit

-$634,000

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the non-alcoholic beverages peer group is "buy"

  • Wall Street's median 12-month price target for Zevia PBC is $5.00, about 34.4% above its August 5 closing price of $3.28

Press Release: ID:nBw28pNqda

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10